Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

YM BioSciences Inc. (YMB)

  Print      Mail a friend

Friday 20 June, 2008

YM BioSciences Inc.


Attention Business Editors:

    - Dr. Ali Raza To Lead Further Development Of AeroLEF As President Of
    AeroLEF Division -

    MISSISSAUGA, ON, June 19 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM,
AIM: YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announced that the
Clinical Hold imposed by the US Food and Drug Administration (FDA) on the
development of YM's AeroLEF(R) has been lifted. The lifting of this Hold
permits YM to resume the expansion into the US of the Phase II clinical
development of AeroLEF.
    AeroLEF is being developed as a novel and effective approach to the
management of acute pain by delivering a proprietary formulation of inhaled,
nebulized, free-and-liposome-encapsulated fentanyl. The free fentanyl results
in rapid onset of analgesia while the liposome-encapsulated fentanyl produces
the unique extended duration of pain relief. The FDA cleared a Phase II
protocol in June 2007 to proceed with AeroLEF's first trial in the US,
however, immediately prior to the End-of-Phase II meeting scheduled and held
in January 2008, the FDA imposed a Clinical Hold, now lifted.
    YM is also pleased to announce that Dr. Ali Raza has been engaged as
President of the AeroLEF Division to lead the product's further development.
Dr. Raza has held a number of leadership roles in established and
development-stage pharmaceutical companies. He led the global development of
CRESTOR(R) (rosuvastatin), a product approved in more than 60 countries and
which is competing for market leadership with Lipitor(R). Earlier this year he
achieved regulatory clearance for and initiated a major Phase III clinical
program for a fentanyl product being developed in more than 50 research
centers in Europe.
    "I am delighted to have joined the AeroLEF team at YM BioSciences and
look forward to moving rapidly to the late-stage, international development of
this unique product," said Dr. Raza.
    "We welcome Dr. Raza and have high confidence that his breadth of
experience in global drug development will significantly reinforce our team's
ability to realize the substantial value of AeroLEF's unique approach to the
treatment of pain. The scientific pedigree and unique advantages of this
product have been established and safety and efficacy data have been reported
from previous clinical trials, including in three poster presentations at the
Annual Meeting of the American Pain Society in May 2008," said David Allan,
Chairman and CEO. "We also greatly appreciate the timely review by the FDA to
our responses and the constructive approach of the Agency."

    About YM BioSciences

    YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. In addition to
AeroLEF, the Company's other late-stage product, nimotuzumab, is a humanized
monoclonal antibody that targets the epidermal growth factor receptor (EGFR).
It is approved in several countries for treatment of various types of head and
neck cancer.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(TM) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or

For further information: Enquiries: James Smith, the Equicom Group Inc., Tel.
(416) 815-0700 x 229, Email: jsmith(at); Thomas Fechtner, the
Trout Group LLC, Tel. (646) 378-2931, Email: tfechtner(at);
Nominated Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. +44 (0)20 7050



a d v e r t i s e m e n t